SCHEMBL186937

SCHEMBL186937

CCCCC(NC(=O)c1ccccc1)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.68
PRSS1 P07477 3/20 0.57
CTSG P08311 3/20 0.57
CTRB1 P17538 3/20 0.57
CMA1 P23946 3/20 0.57
FOLH1 Q04609 4/20 0.55
CYP1A2 P05177 2/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
TSHR P16473 1/20 0.55
CYP2C19 P33261 1/20 0.55
MME P08473 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
LMNA P02545 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
HSD17B10 Q99714 1/20 0.53
C3AR1 Q16581 1/20 0.52
NAAA Q02083 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186935 1.00 CA2 (0.68) CA2PRSS1CTSGCTRB1CMA1
SCHEMBL10668269 1.00 CA2 (0.68) CA2PRSS1CTSGCTRB1CMA1
Ammonia Solution, Strong SCHEMBL11218438 0.98 CA2 (0.67) CA2PRSS1CTSGCTRB1CMA1
SCHEMBL24064866 0.95 CA2 (0.63) CA2PRSS1CTSGCTRB1CMA1
SCHEMBL29036089 0.94 CA2 (0.61) CA2PRSS1CTSGCTRB1CMA1
SCHEMBL7759090 0.94 CA2 (0.61) CA2PRSS1CTSGCTRB1CMA1
SCHEMBL3082006 0.93 CA2 (0.76) CA2FOLH1NPC1RAB9ACA12
SCHEMBL9829285 0.90 RAB9A (0.60) CA2PRSS1CTSGCTRB1CMA1
SCHEMBL3948327 0.90 RAB9A (0.60) CA2PRSS1CTSGCTRB1CMA1
SCHEMBL12809901 0.89 PRSS1 (0.56) CA2PRSS1CTSGCTRB1CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114903853-A PH-sensitive drug-loaded copolymer micelle and preparation method and application thereof 沈阳药科大学 2022-08-16 CN claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
JP-57014659-A None JP disclosed
JP-6220385-A None JP disclosed
CN-114903853-A PH-sensitive drug-loaded copolymer micelle and preparation method and application thereof 沈阳药科大学 2022-08-16 CN disclosed
US-11339184-B2 Antibacterial compounds, compositions thereof, and methods using same THE ROCKEFELLER UNIVERSITY (US) 2022-05-24 US disclosed
WO-2021242849-A1 ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME THE ROCKEFELLER UNIVERSITY (US) 2021-12-02 WO disclosed
US-20210024562-A1 ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME THE ROCKEFELLER UNIVERSITY 2021-01-28 US disclosed
CN-110382572-A Curing type aqueous resin emulsion compositions 昭和电工株式会社 2019-10-25 CN disclosed
US-8580747-B2 Cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
US-4621092-A HYPOTENSIVE, ANALGESIC E. R. SQUIBB & SONS, INC. (US) 1986-11-04 US disclosed
US-4604402-A HYPOTENSIVE AGNETS E. R. SQUIBB & SONS, INC. (US) 1986-08-05 US disclosed
EP-0159156-A1 Hydroxy substituted ureido amino and imino acids E.R. Squibb & Sons, Inc. (US) 1985-10-23 EP disclosed
US-4535176-A HYPOTENSIVE AGENTS, ANALGESICS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS E. R. SQUIBB & SONS, INC. (US) 1985-08-13 US disclosed
US-4470973-A HYPOTENSIVE AGENTS, ANALGESICS E. R. SQUIBB & SONS, INC. (US) 1984-09-11 US disclosed
EP-0103496-A1 Acylalkylaminocarbonyl substituted amino and imino acid compounds E.R. Squibb & Sons, Inc. (US) 1984-03-21 EP disclosed
EP-0036713-B1 ANGIOTENSIN CONVERTING ENZYME INHIBITORS UNIVERSITY OF MIAMI (US) 1984-01-18 EP disclosed
JP-S5714659-A WATER-BASED INK COMPOSITION PENTEL KK 1982-01-25 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339184-B2 Antibacterial compounds, compositions thereof, and methods using same CLPP, MPO, SPOUT1 CA2 3775/4885PRSS1 2611/4885CTSG 399/4885
US-20210024562-A1 ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME CLPP, MPO, SPOUT1 CA2 3775/4885PRSS1 2611/4885CTSG 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.